Menu
Back to Journals » Lung Cancer: Targets and Therapy » Volume 11 » default
Lung Cancer: Targets and Therapy
ISSN: 1179-2728
- View all (169)
- Volume 14, 2023 (9)
- Volume 13, 2022 (8)
- Volume 12, 2021 (14)
- Volume 11, 2020 (11)
- Volume 10, 2019 (16)
- Volume 9, 2018 (14)
- Volume 8, 2017 (25)
- Volume 7, 2016 (17)
- Volume 6, 2015 (9)
- Volume 5, 2014 (10)
- Volume 4, 2013 (9)
- Volume 3, 2012 (9)
- Volume 2, 2011 (6)
- Volume 1, 2010 (12)
Archive: Volume 11, 2020
Serum Tumor Marker Dynamics as Predictive Biomarkers in NSCLC Chemo-Immunotherapy and Mono-Immunotherapy Maintenance: A Registry-Based Descriptive Study
Lang D, Haslinger W, Akbari K, Scala M, Hergan B, Asel C, Horner A, Wass R, Brehm E, Kaiser B, Lamprecht B
Lung Cancer: Targets and Therapy 2020, 11:113-121
Published Date: 18 December 2020
Clinical Outcomes of Proton Beam Therapy for Ground-Glass Opacity-Type Lung Cancer
Nagata I, Ogino T, Arimura T, Yoshiura T
Lung Cancer: Targets and Therapy 2020, 11:105-111
Published Date: 9 October 2020
A Comprehensive Review of Contemporary Literature for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer and Their Toxicity
Lee CS, Sharma S, Miao E, Mensah C, Sullivan K, Seetharamu N
Lung Cancer: Targets and Therapy 2020, 11:73-103
Published Date: 7 October 2020
Favorable Immune Microenvironment in Patients with EGFR and MAPK Co-Mutations
Yang W, Chen N, Li L, Chen X, Liu X, Zhang Y, Cui J
Lung Cancer: Targets and Therapy 2020, 11:59-71
Published Date: 7 September 2020
Correlation of Immune-Related Adverse Events and Effects of Pembrolizumab Monotherapy in Patients with Non-Small Cell Lung Cancer
Noguchi S, Suminaga K, Kaki T, Kawachi H, Fukao A, Terashita S, Horikawa S, Ikeue T, Sugita T
Lung Cancer: Targets and Therapy 2020, 11:53-57
Published Date: 12 July 2020
Clinical Evaluation of Everolimus in the Treatment of Neuroendocrine Tumors of the Lung: Patient Selection and Special Considerations. A Systematic and Critical Review of the Literature
Peri M, Fazio N
Lung Cancer: Targets and Therapy 2020, 11:41-52
Published Date: 8 July 2020
Patients with NSCLCs Harboring Internal Inversions or Deletion Rearrangements of the ALK Gene Have Durable Responses to ALK Kinase Inhibitors
Schrock AB, Madison R, Rosenzweig M, Allen JM, Erlich RL, Wang SY, Chidiac T, Reddy VS, Riess JW, Yassa AE, Shakir A, Miller VA, Alexander BM, Venstrom J, McGregor K, Ali SM
Lung Cancer: Targets and Therapy 2020, 11:33-39
Published Date: 17 April 2020
Orphan Drugs in Development for the Treatment of Small-Cell Lung Cancer: Emerging Data on Lurbinectedin
Kauffmann-Guerrero D, Huber RM
Lung Cancer: Targets and Therapy 2020, 11:27-31
Published Date: 2 March 2020
Incidence of ROS1-Rearranged Non-Small-Cell Lung Carcinoma in India and Efficacy of Crizotinib in Lung Adenocarcinoma Patients
Mehta A, Saifi M, Batra U, Suryavanshi M, Gupta K
Lung Cancer: Targets and Therapy 2020, 11:19-25
Published Date: 24 February 2020
Symptomatic CNS Radiation Necrosis Requiring Neurosurgical Resection During Treatment with Lorlatinib in ALK-Rearranged NSCLC: A Report of Two Cases
Zhu VW, Nagasaka M, Kubota T, Raval K, Robinette N, Armas O, Al-Holou W, Ou SI
Lung Cancer: Targets and Therapy 2020, 11:13-18
Published Date: 14 January 2020
The Current Understanding Of Asbestos-Induced Epigenetic Changes Associated With Lung Cancer
Cheng YY, Rath EM, Linton A, Yuen ML, Takahashi K, Lee K
Lung Cancer: Targets and Therapy 2020, 11:1-11
Published Date: 8 January 2020